Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | qPCR, Flow cytometric assay, Luciferase reporter assay, Western blot, etc. |
| Sample | Fifteen pairs of RCC samples, adjacent non-tumor tissues. Human RCC cell lines(OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P). |
| Expression Pattern | down-regulated |
| Function Description | Our findings suggested that GAS5 downregulation may be a new marker of poor response to sorafenib and GAS5 could be a potential therapeutic target for sorafenib treatment in RCC. Mechanistically, GAS5 functioned as competing endogenous RNA to repress miR-21, which controlled its down-stream target SOX5. |
| Pubmed ID | 29895198 |
| Year | 2018 |
| Title | Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway. |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for renal cell carcinoma | OMIM COSMIC |